World J Gastroenterol. 2010 April 28; 16(16): 2005-2009.
Published online 2010 April 28. doi: 10.3748/wjg.v16.i16.2005.
©2010 Baishideng. All rights reserved.
Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection
Farah Bokharaei Salim, Hossein Keyvani, Fatemeh Jahanbakhsh Sefidi, Virology Department, Iran University of Medical Sciences, Tehran 14114, Iran
Afsaneh Amiri, Farhad Zamani, GI and Liver Disease Research Centre, Iran University of Medical Sciences, Tehran 14114, Iran
Ramin Shakeri, Digestive Disease Research Centre, Tehran University of Medical Sciences, Tehran 14114, Iran
Received January 4, 2010; Revised February 3, 2010; Accepted February 10, 2010;
AIM: To investigate the presence of mixed infection and discrepancy between hepatitis C virus (HCV) genotypes in plasma, peripheral blood mononuclear cells (PBMCs), and liver biopsy specimens.
METHODS: From September 2008 up to April 2009, 133 patients with chronic hepatitis C referred to Firouzgar Hospital for initiation of an antiviral therapy were recruited in the study. Five milliliters of peripheral blood was collected from each patient and liver biopsy was performed in those who gave consent or had indications. HCV genotyping was done using INNO-LiPA™ HCV II in serum, PBMCs, and liver biopsy specimens and then confirmed by sequencing of 5’-UTR fragments.
RESULTS: The mean age of patients was 30.3 ± 17.1 years. Multiple transfusion was seen in 124 (93.2%) of patients. Multiple HCV genotypes were found in 3 (2.3%) of 133 plasma samples, 9 (6.8%) of 133 PBMC samples, and 8 (18.2%) of 44 liver biopsy specimens. It is notable that the different genotypes found in PBMCs were not the same as those found in plasma and liver biopsy specimens.
CONCLUSION: Our study shows that a significant proportion of patients with chronic hepatitis C are affected by multiple HCV genotypes which may not be detectable only in serum of patients.
Keywords: Chronic hepatitis C virus infection, Mixed hepatitis C virus infection, Peripheral blood mononuclear cells, Hepatocyte
Hepatitis C virus (HCV) is an enveloped positive-stranded RNA virus of the family Flaviviridae and genus Hepacivirus that causes both acute and chronic hepatitis[1-3
]. HCV is a major health problem affecting 170 million people worldwide[4
]. It is estimated that chronic HCV infection is responsible for approximately 250 000 to 350 000 deaths per year, mainly related to decompensation of cirrhosis, end-stage liver disease, and hepatocellular carcinoma[5
Phylogenetic analysis of HCV sequences resulted in a nomenclature that recognizes distinct virus types and subtypes[6
]. Six large groups of viral genotypes[7-12
], in addition to over 70 different subtypes (termed a, b, c, etc
.) are distributed worldwide[6,13
]. The HCV genotypes should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure[14
The HCV is considered as essentially hepatotropic[15
], but virus sequences have also been found in other important extrahepatic sites, including peripheral blood mononuclear cells (PBMCs), the central nervous system, and bone marrow from chronically-infected patients[16-19
HCV replicates through a negative-strand intermediary. Although hepatocytes are the primary sites for HCV replication, there is evidence of negative-strand HCV RNA in PBMCs. The HCV genomic sequences present in PBMCs have been found to differ from those found in serum and the liver biopsy specimens[20-24
]. Detection of HCV RNA in extrahepatic reservoirs has important implications for transmission, disease progression, and effective treatment[25
]. Furthermore, the PBMC compartment may be a privileged site for HCV, which is able to reinitiate viral replication after termination of HCV treatment when conditions again become more favorable. Re-infection of HCV after orthotropic liver transplantation has postulated that extrahepatic sites are suitable for HCV replication[26
]. Thus, even if clearance of HCV from hepatocytes is achieved by treatment, re-infection from extrahepatic sites, such as the PBMC compartment, may occur[27
The purpose of the present study is to determine the presence and frequency of different HCV genotypes in plasma, PBMC, and liver biopsy specimens of chronically infected patients.
MATERIALS AND METHODS
In this cross-sectional study, 133 consecutive patients with established chronic hepatitis C referred to Firouzgar Hospital from September 2008 to July 2009 were enrolled. Informed consents were obtained from the patients, and the study was approved by the local ethics committee of GI and Liver Disease Research centre (GILDRC) of Iran University of Medical Sciences.
Inclusion criteria were positive anti-HCV antibodies along with positive plasma HCV RNA. Also none of the included patients had been treated for HCV previously.
Collection and preparation of samples
About 5 mL of peripheral blood were collected from each patient into EDTA-containing vacutainer tubes. Plasma was stored at -70°C until analysis. PBMCs were isolated from EDTA-treated blood by centrifugation over density gradient (Lymphoprep, Oslo, Norway). PBMCs were then washed three times with phosphate-buffered saline (pH = 7.4), counted and stored at -70°C for later detection. Some of the patients who gave consent underwent a liver biopsy for diagnostic purpose. Liver biopsy specimens were divided into 2 portions: one used for histological diagnosis, and the second was submerged into RNALater (Ambion Inc., Austin, TX) and stored at -70°C for HCV genotyping. Samples of serum and PBMCs were collected from all patients on the same day the liver biopsy was performed.
Isolation of RNA from serum, PBMCs, and liver
RNA was extracted from 140 μL of plasma by using the QIAamp Viral RNA Extraction kit (Qiagen GmbH, Hilden, Germany), from a pellet of approximately 3-5 × 106 PBMCs using the RNA Virus Mini Extraction Kit (Invitek GmbH, Germany), and from approximately 2 mm3 of liver biopsy specimens using the DNA/RNA Virus Mini Extraction Kit (Invitek GmbH, Germany), according to the manufacturer’s instructions.
RNA was isolated from plasma, PBMC, and liver biopsy specimens as described above. 5’-untranslated region (5’-UTR) genotyping was done using a standard methodology with the INNO-LiPA™ HCV II kit (Innogenetics, Ghent, Belgium) according to the manufacturer’s instructions. Briefly, the 5’-UTR is amplified with biotinylated primers. Biotin-labeled PCR products are reverse hybridized to specific probes attached to nitrocellulose strips and then incubated with a chromogen. Developing results in a purple precipitate that forms a line on the strip. The HCV type is deduced on the basis of the patterns of hybridizing bands, using the line probe assay interpretation chart[28
INNO-LiPA™ HCV II genotyping has also been confirmed by sequencing of 5’-UTR fragments. The HCV 5’-UTR was amplified from total RNA isolated from plasma, PBMC, and liver biopsy specimens of 10 randomly selected patients by reverse transcriptase-PCR as described previously[29
]. The 211-bp 5’-UTR PCR products were sequenced by dye termination method using the ABI 3130 XL sequencer. The sequencing results were compared with other sequences posited in gene bank by Blast software.
Data analysis was done by SPSS software version 16.0, using descriptive statistical indexes such as mean and standard deviation (SD), 95% confidence interval (CI) and t test. P value less than 0.05 was considered statistically significant.
One hundred and thirty three patients with established chronic hepatitis C were recruited in this study. Multiple blood transfusion was the most important related risk factor found in 124 (93.2%) of patients, 87 (65.4%) with thalassemia and 37 (27.8%) with hemophilia. The source of infection was unknown in 9 (6.8%) patients. The mean age of patients was 30.3 ± 17.1 years. Out of 133 patients, 100 (75.2%) were male. The mean viral load of all of the patients was 6.3 × 105 ± 7.8 × 105 (range from 45 000 to 5.59 × 106). Out of 133 patients, 44 patients gave consent to undergo liver biopsy. Genotype 1a was the most frequent genotype in serum (63.9%), PBMCs (61.0%), and in liver biopsy specimens (54.5%). HCV genotypes in serum, PBMCs, and liver biopsy specimens of all patients were similar except for 20 patients (15%).
The complete data of these patients have been summarized in Table . As shown in Table , more than one HCV genotype has been found in some patients, as 3 (2.3%) patients had different HCV genotypes in their serum samples. In 9 (6.8%) patients, different HCV genotypes were found in PBMCs. In 8 (18.2%) patients (who were not exactly same as the 9 patients with different HCV genotypes in PBMCs) multiple HCV genotypes were found in liver biopsy specimens. The INNO-LiPA™ HCV II genotyping was confirmed with sequencing of the 5’-UTR. A 100% correlation was demonstrated between INNO-LiPA™ HCV II genotyping and sequencing of the 5’-UTR.
Distribution of different HCV genotypes in plasma, PBMCs, and liver biopsy specimens
Frequency of HCV genotypes in plasma, PBMCs, and liver biopsy specimens n (%)
The present study was performed on 133 chronically HCV infected patients to evaluate the prevalence of potential mixed HCV infection in their plasma, PBMCs, and liver biopsy specimens. In 15% of these patients different HCV genotypes were found in these compartments. Multiple HCV genotypes were detected in 3 (2.3%) of 133 plasma, 9 (6.8%) of 133 PBMC, and 8 (18.2%) of 44 liver biopsy specimens.
Mixed infection is infection of an individual with two or more distinct HCV genotypes. Mixed viral infection is of great clinical importance as it may result in more severe disease, unresponsiveness to antiviral therapy or recurrence after the completion of antiviral therapy course[30
In our study, various HCV genotypes presented in PBMCs were different from those found in plasma or liver biopsy specimens (Table ). It means that PBMCs may present some divergent types, which are not detectable in liver biopsy specimens. It reinforces the previous proposed theories in which PBMCs have been known as an extrahepatic replication site for HCV[17,25,26,31-34
It is suggested that infection with one HCV type doesn’t make a barrier to acquisition of other genotypes, therefore multiple exposures to HCV especially in potential risk groups, might lead to several episodes of re-infection and to the establishment of mixed infection in some patients. It is also well known that super infection with a new HCV strain leads to suppression of one virus under the detection limit of PCR while the other one prevails as under antiviral therapy, the displaced strain may become viremic again and may alter the outcome of therapy[30,35-39
In our study the prevalence of mixed HCV infection was estimated about 2.3% in plasma, 6.8% in PBMC, and 18.2% in liver biopsy specimens of chronically infected patients with HCV. Mixed infection with two HCV genotypes have been detected in 1% of HCV-positive patients, using type-specific primers[40,41
]. Also figures of 1.6% to 31% have been reported in multi-transfused hemophiliacs[42,43
Our study demonstrated that a significant proportion of HCV infected patients have divergent HCV genotypes in their PBMCs and liver biopsy specimens which were not detectable in their plasma.
In the present study we used INNO-LiPA™ HCV II genotyping which is currently the most applied method and has more sensitivity than RFLP. One of the problems of INNO-LiPA™ HCV II is that it may underestimate the actual rate of mixed infection[9,30,44
]. According to this, the true prevalence of mixed infection may be higher than estimated in this study.
The second shortcoming is that only 44 of our patients had indication or gave consent to undergo liver biopsy, however, 18.2% of them had multiple HCV genotypes which is a significant proportion of the total. It indicates that hepatocytes are the main reservoirs for HCV. On the other hand since performance of liver biopsy is not possible for all patients, we suggest the assessment of PBMCs as another HCV reservoir for detection of HCV mixed infection[26,34,45
In conclusion, our study shows that patients with hemophilia and thalassemia are from the most high risk groups in whom mixed infection is relatively common. On the other hand failure to treatment and relapse of infection is also frequent in these groups. So it seems that considering the plasma genotype as the target genotype for scheduling of an anti HCV therapy may be one of the factors that leads to the failure of treatment. HCV genotyping in PBMCs or liver biopsy specimens might be beneficial.
Relapse and failure of antiviral therapy have been frequently seen in patients with chronic hepatitis C especially in those who are on multiple blood transfusions.
It has been suggested that infection with multiple hepatitis C virus (HCV) genotypes in patients affected by chronic HCV infection might result in frequent relapse after antiviral therapy.
Innovations and breakthroughs
The authors found that a significant proportion of patients with chronic HCV infection, especially who are on chronic blood transfusion, might present more than one HCV genotype in their serum, hepatocytes and peripheral blood mononuclear cells (PBMCs). It is notable that detected HCV genotypes in serum may be different from those found in PBMCS or hepatocytes.
According to the above findings the authors suggest HCV genotyping in hepatocytes and PBMCs along with serum of patients. This may result in choosing a more appropriate antiviral therapy in these patients.
This is a well written manuscript and it addresses a relevant topic of multiple HCV infections/superinfection/humoral protection and others. Moreover, the material itself is of some value.
Rho J, Ryu JS, Hur W, Kim CW, Jang JW, Bae SH, Choi JY, Jang SK, Yoon SK. Hepatitis C virus (HCV) genotyping by annealing reverse transcription-PCR products with genotype-specific capture probes. J Microbiol.
Liew M, Erali M, Page S, Hillyard D, Wittwer C. Hepatitis C genotyping by denaturing high-performance liquid chromatography. J Clin Microbiol.
Ducoulombier D, Roque-Afonso AM, Di Liberto G, Penin F, Kara R, Richard Y, Dussaix E, Féray C. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology.
Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bartolomé J, Carreño V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis.
Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol.
Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, Simmonds P. The origin of hepatitis C virus genotypes. J Gen Virol.
Kubo Y, Takeuchi K, Boonmar S, Katayama T, Choo QL, Kuo G, Weiner AJ, Bradley DW, Houghton M, Saito I. A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. Nucleic Acids Res.
Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science.
Hoofnagle JH. Course and outcome of hepatitis C. Hepatology.
Seeff LB. Natural history of chronic hepatitis C. Hepatology.
Pawlotsky JM. The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis.
Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology.
Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med.
Trimoulet P, Bernard PH, de Ledinghen V, Oui B, Chene G, Saint-Marc Girardin MF, Dantin S, Couzigou P, Fleury H. Quantitation of hepatitis C virus RNA in plasma and peripheral blood mononuclear cells of patients with chronic hepatitis treated with interferon-alpha. Dig Dis Sci.
Majda-Stanisławska E, Bednarek M, Jóźwiak B, Sidorkiewicz M, Piekarska A, Kuydowicz J. Effect of interferon alfa and ribavirin treatment on hepatitis C virus RNA in serum and peripheral blood mononuclear cells in children with chronic hepatitis C. Acta Gastroenterol Belg.
Xu DZ, Xie Y, Li ZQ. Clearance of HCV RNA in peripheral blood mononuclear cell as a predictor of response to antiviral therapy in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int.
Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol.
Kusaka S, Okusa T, Araki A, Fujiki K, Takashimizu I, Okayasu I, Yamamoto N, Sato C. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells. J Med Virol.
Laskus T, Radkowski M, Wang LF, Jang SJ, Vargas H, Rakela J. Hepatitis C virus quasispecies in patients infected with HIV-1: correlation with extrahepatic viral replication. Virology.
Laskus T, Radkowski M, Wang LF, Nowicki M, Rakela J. Uneven distribution of hepatitis C virus quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extrahepatic replication. J Virol.
Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud MA, Trépo C, Inchauspé G. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood.
Navas S, Martín J, Quiroga JA, Castillo I, Carreño V. Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients. J Virol.
Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D, Feray C. Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology.
Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ, Rodriguez I, Mayer KH, Chung RT. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis.
Gong GZ, Lai LY, Jiang YF, He Y, Su XS. HCV replication in PBMC and its influence on interferon therapy. World J Gastroenterol.
Cavalheiro Nde P, Filgueiras TC, Melo CE, Morimitsu SR, de Araújo ES, Tengan FM, Barone AA. Detection of HCV by PCR in serum and PBMC of patients with hepatitis C after treatment. Braz J Infect Dis.
Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol.
Schröter M, Zöllner B, Schäfer P, Laufs R, Feucht HH. Comparison of three HCV genotyping assays: a serological method as a reliable and inexpensive alternative to PCR based assays. J Clin Virol.
White PA, Li Z, Zhai X, Marinos G, Rawlinson WD. Mixed viral infection identified using heteroduplex mobility analysis (HMA). Virology.
Laskus T, Operskalski EA, Radkowski M, Wilkinson J, Mack WJ, deGiacomo M, Al-Harthi L, Chen Z, Xu J, Kovacs A. Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis.
Castillo I, Rodríguez-Iñigo E, Bartolomé J, de Lucas S, Ortíz-Movilla N, López-Alcorocho JM, Pardo M, Carreño V. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut.
Lerat H, Berby F, Trabaud MA, Vidalin O, Major M, Trépo C, Inchauspé G. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest.
Di Liberto G, Féray C. The anhepatic phase of liver transplantation as a model for measuring the extra-hepatic replication of hepatitis C virus. J Hepatol.
Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N. Lack of protective immunity against reinfection with hepatitis C virus. Science.
Jarvis LM, Watson HG, McOmish F, Peutherer JF, Ludlam CA, Simmonds P. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis.
Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, Farci P. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet.
Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspé G. Immunity in hepatitis C infection. J Infect Dis.
Widell A, Månsson S, Persson NH, Thysell H, Hermodsson S, Blohme I. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation.
Holland PV, Barrera JM, Ercilla MG, Yoshida CF, Wang Y, de Olim GA, Betlach B, Kuramoto K, Okamoto H. Genotyping hepatitis C virus isolates from Spain, Brazil, China, and Macau by a simplified PCR method. J Clin Microbiol.
Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol.
Telfer PT, Devereux H, Savage K, Scott F, Dhillon AP, Dusheiko G, Lee CA. Chronic hepatitis C virus infection in haemophilic patients: clinical significance of viral genotype. Thromb Haemost.
Isobe K, Imoto M, Fukuda Y, Koyama Y, Nakano I, Hayakawa T, Takamatsu J. Hepatitis C virus infection and genotypes in Japanese hemophiliacs. Liver.
Qian KP, Natov SN, Pereira BJ, Lau JY. Hepatitis C virus mixed genotype infection in patients on haemodialysis. J Viral Hepat.
Roque-Afonso AM, Ducoulombier D, Di Liberto G, Kara R, Gigou M, Dussaix E, Samuel D, Féray C. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol.